144 related articles for article (PubMed ID: 31004012)
1. Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine.
Matsuda K; Huang J; Zhou T; Sheng Z; Kang BH; Ishida E; Griesman T; Stuccio S; Bolkhovitinov L; Wohlbold TJ; Chromikova V; Cagigi A; Leung K; Andrews S; Cheung CSF; Pullano AA; Plyler J; Soto C; Zhang B; Yang Y; Joyce MG; Tsybovsky Y; Wheatley A; Narpala SR; Guo Y; Darko S; Bailer RT; Poole A; Liang CJ; Smith J; Alexander J; Gurwith M; Migueles SA; Koup RA; Golding H; Khurana S; McDermott AB; Shapiro L; Krammer F; Kwong PD; Connors M
Sci Immunol; 2019 Apr; 4(34):. PubMed ID: 31004012
[TBL] [Abstract][Full Text] [Related]
2. A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.
Matsuda K; Migueles SA; Huang J; Bolkhovitinov L; Stuccio S; Griesman T; Pullano AA; Kang BH; Ishida E; Zimmerman M; Kashyap N; Martins KM; Stadlbauer D; Pederson J; Patamawenu A; Wright N; Shofner T; Evans S; Liang CJ; Candia J; Biancotto A; Fantoni G; Poole A; Smith J; Alexander J; Gurwith M; Krammer F; Connors M
J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33529172
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
4. [Study on the immunogenicity of adeno-vector vaccine against H5N1 influenza A virus].
Zhang XG; Li KB; Ma J; Wang NF; Zhang XM; Sang YH; Dong J; Xu H; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):97-9. PubMed ID: 20104746
[TBL] [Abstract][Full Text] [Related]
5. Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.
de Vries RD; Altenburg AF; Nieuwkoop NJ; de Bruin E; van Trierum SE; Pronk MR; Lamers MM; Richard M; Nieuwenhuijse DF; Koopmans MPG; Kreijtz JHCM; Fouchier RAM; Osterhaus ADME; Sutter G; Rimmelzwaan GF
J Infect Dis; 2018 Jul; 218(4):614-623. PubMed ID: 29912453
[TBL] [Abstract][Full Text] [Related]
6. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
7. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.
Alexander J; Ward S; Mendy J; Manayani DJ; Farness P; Avanzini JB; Guenther B; Garduno F; Jow L; Snarsky V; Ishioka G; Dong X; Vang L; Newman MJ; Mayall T
PLoS One; 2012; 7(2):e31177. PubMed ID: 22363572
[TBL] [Abstract][Full Text] [Related]
9. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.
Gao W; Soloff AC; Lu X; Montecalvo A; Nguyen DC; Matsuoka Y; Robbins PD; Swayne DE; Donis RO; Katz JM; Barratt-Boyes SM; Gambotto A
J Virol; 2006 Feb; 80(4):1959-64. PubMed ID: 16439551
[TBL] [Abstract][Full Text] [Related]
10. Construction of a recombinant duck enteritis virus (DEV) expressing hemagglutinin of H5N1 avian influenza virus based on an infectious clone of DEV vaccine strain and evaluation of its efficacy in ducks and chickens.
Wang J; Ge A; Xu M; Wang Z; Qiao Y; Gu Y; Liu C; Liu Y; Hou J
Virol J; 2015 Aug; 12():126. PubMed ID: 26263920
[TBL] [Abstract][Full Text] [Related]
11. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
[TBL] [Abstract][Full Text] [Related]
12. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.
Shoji Y; Chichester JA; Jones M; Manceva SD; Damon E; Mett V; Musiychuk K; Bi H; Farrance C; Shamloul M; Kushnir N; Sharma S; Yusibov V
Hum Vaccin; 2011; 7 Suppl():41-50. PubMed ID: 21266846
[TBL] [Abstract][Full Text] [Related]
13. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
[TBL] [Abstract][Full Text] [Related]
14. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
15. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
16. An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice.
Kim EH; Han GY; Nguyen H
Viruses; 2017 Aug; 9(8):. PubMed ID: 28825679
[TBL] [Abstract][Full Text] [Related]
17. H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem.
Wheatley AK; Whittle JR; Lingwood D; Kanekiyo M; Yassine HM; Ma SS; Narpala SR; Prabhakaran MS; Matus-Nicodemos RA; Bailer RT; Nabel GJ; Graham BS; Ledgerwood JE; Koup RA; McDermott AB
J Immunol; 2015 Jul; 195(2):602-10. PubMed ID: 26078272
[TBL] [Abstract][Full Text] [Related]
18. Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains.
Rauw F; Palya V; Van Borm S; Welby S; Tatar-Kis T; Gardin Y; Dorsey KM; Aly MM; Hassan MK; Soliman MA; Lambrecht B; van den Berg T
Vaccine; 2011 Mar; 29(14):2590-600. PubMed ID: 21292007
[TBL] [Abstract][Full Text] [Related]
19. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
[TBL] [Abstract][Full Text] [Related]
20. Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge.
Wang X; Fu W; Yuan S; Yang X; Song Y; Liu L; Chi Y; Cheng T; Xing M; Zhang Y; Zhang C; Yang Y; Zhu C; Zhang X; Xiong S; Xu J; Zhou D
Sci Rep; 2017 May; 7(1):1854. PubMed ID: 28500340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
